Clinical trial / 2007
DHA from two algal oil capsule sources and an algal-DHA-fortified snack bar showed equivalent bioavailability and a dose-dependent response.
A 28-day randomized, placebo-controlled study evaluated the bioequivalence of two algal DHA oils in capsules (DHASCO-T and DHASCO-S at 200, 600, and 1,000 mg DHA/day; n = 12 per group) and an algal-DHA-fortified food (n = 12). Both capsule types produced equivalent DHA levels in plasma phospholipids and erythrocytes, with dose-dependent and linear increases in plasma phospholipid DHA of 1.17, 2.28, and 3.03 g per 100 g fatty acid at 200, 600, and 1,000 mg doses, respectively. Snack bars fortified with DHASCO-S delivered equivalent DHA on a dose basis. Adverse event monitoring showed an excellent safety and tolerability profile.
- Study type
- 28-day randomized, placebo-controlled, parallel-group study
- Who was studied
- Participants randomized into groups of n = 12 per group
- What was measured
- Changes in plasma phospholipid and erythrocyte DHA levels; effects on ARA, DPAn-6, and EPA
THE PAPER
Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food.
Arterburn LM, Oken HA, Hoffman JP, Bailey-Hall E, Chung G, Rom D, Hamersley J, McCarthy D. Lipids, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.